Table 2.

Clinical characteristics and pregnancy outcomes of the patients according to the concentration of AF PGF2a

	Low PGF2a (n=94)	High PGF2a (n=46)	P
Maternal age (y)	30 (23–45)	30 (21–38)	NS
Nulliparity (n)	42 (45%)	16 (35%)	NS
GA at amniocentesis (week)*	32.6 (20.4–35.0)	30.5 (21.6–34.7)	NS
GA at delivery (week)*	34.3 (23.7–41.6)	31.5 (21.9–35.7)	<.001
Amniocentesis-to-delivery interval (hour)†	155 (0–3545)	72 (0–1849)	<.001
within 48 hours	14 (15%)	20 (44%)	<.001
within 7 days	52 (55%)	37 (80%)	<.005
Preterm delivery <36 weeks	80 (85%)	46 (100%)	<.005
Positive AF culture	10 (11%)	18 (39%)	<.001
Intraamniotic infection/inflammation ‡	22 (23%)	37 (80%)	<.001
AF WBC (cells/mm3)*	1 (0–621)	397 (0- >1000)	<.001
AF MMP-8 (ng/mL)*	1.8 (0.3–260.5)	267.0 (0.3–5019.5)	<.001
Clinical chorioamnionitis	4 (4%)	4 (9%)	NS
Histologic chorioamnionitis (n/N)	39/72 (54%)	24/36 (67%)	NS
Funisitis (n/N)	21/74 (28%)	20/36 (56%)	<.01

Values are medians and ranges.

AF, amniotic fluid; MMP-8, matrix metalloproteinase-8; Low PGF2a, PGF2a <170 pg/mL; High PGF2a, PGF2a ≥170 pg/mL; GA, gestational age; NS, not significant; WBC, white blood cell

^*P<.05, by Kruskal-Wallis ANOVA test

^†Compared by generalized Wilcoxon test for survival analysis.

^‡Intraamniotic infection/inflammation was defined as a positive AF culture and/or elevated AF MMP-8 concentration (>23ng/ml).